Our break-through recombinant DNA biotechnology for the construction of a new generation vaccines, biologics, biosimilars, industrial and environmental processes has been granted with United States patent. We are awaiting for issuing the patent number (the application number 2017/0095553 A1).
top of page
bottom of page